Advertisement
New Zealand markets closed
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NZD/USD

    0.6021
    -0.0013 (-0.21%)
     
  • NZD/EUR

    0.5584
    -0.0010 (-0.18%)
     
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • NZD/JPY

    93.7530
    -0.0150 (-0.02%)
     

A Look at Insys Therapeutics’ Financial Performance

A Look at Insys Therapeutics’ Financial Performance

Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.